IXICO shares jump 9% after playing key role in FDA-approved Alzheimer's blood test

IXICO shares rose 9% following the FDA approval of Fujirebio Diagnostics’ Lumipulse blood test for Alzheimer’s disease, for which IXICO provided key imaging analysis. The UK-listed company's AI-driven analysis of brain scan data from the Bio-Hermes-001 study supported the test's validation, offering a less invasive alternative to traditional diagnostic methods. The Lumipulse test, intended for patients 50 and over with memory issues, is expected to improve early diagnosis and screening efficiency.

Analysis

IXICO PLC (LSE:IXI) shares experienced a 9% uplift, trading 1p higher at 12.5p, following confirmation of its pivotal role in the development of Fujirebio Diagnostics’ Lumipulse test, the first FDA-approved blood test for Alzheimer’s disease diagnosis. The UK-based neuro-imaging specialist applied its artificial intelligence tools to analyse data and standardize brain scan readings for the Bio-Hermes-001 study, which served as the gold-standard comparator for the Lumipulse test. This test, which received US regulatory clearance in May, detects key amyloid-linked proteins via a simple blood sample, offering a significantly less invasive and more scalable diagnostic alternative to traditional brain scans or spinal taps for patients aged 50 and over with memory issues. The development is anticipated to accelerate early Alzheimer's diagnosis and enhance screening efficiency in both clinical practice and drug development. The positive market reaction, reflected in a "strongly positive" sentiment score of 0.85 and a market impact score of 0.65, builds on a recent share price surge, with IXICO shares having risen 35% in the last month, underscoring the perceived significance of this advancement within the Healthcare & Biotech and AI sectors.

Key Decisions for Investors

• Investors should acknowledge the significant positive development and the recent 35% share price appreciation over the past month when evaluating new or additional positions in IXICO.
• Closely monitor the commercial success of Fujirebio's Lumipulse test and, crucially, IXICO's ability to convert its validated AI-imaging analysis expertise into future revenue-generating projects within the neurodegenerative disease space.
• Evaluate the long-term strategic value of IXICO's specialized AI expertise in neuro-imaging, particularly its application in high-impact areas like Alzheimer's, which positions the company favorably within key innovation themes.